Paradigm Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Paradigm Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,500	Closed	-$39K	–	449
2025 Q4	$39K	Hold	2,500	–	–	0.01%	430
2025 Q3	$36.6K	Hold	2,500	–	–	0.01%	420
2025 Q2	$38.6K	Hold	2,500	–	–	0.01%	424
2025 Q1	$37.2K	Hold	2,500	–	–	0.01%	433
2024 Q4	$33.1K	Sell	2,500 -300	-11%	-$4.12K	0.01%	436
2024 Q3	$39.8K	Sell	2,800 -500	-15%	-$7.09K	0.01%	418
2024 Q2	$42.7K	Hold	3,300	–	–	0.01%	416
2024 Q1	$45.8K	Hold	3,300	–	–	0.01%	433
2023 Q4	$47.1K	Hold	3,300	–	–	0.01%	432
2023 Q3	$51.1K	Buy	3,300 +800	+32%	+$12.4K	0.01%	419
2023 Q2	$39.3K	Hold	2,500	–	–	0.01%	428
2023 Q1	$41.2K	Hold	2,500	–	–	0.01%	420
2022 Q4	$39K	Hold	2,500	–	–	0.01%	435
2022 Q3	$32.4K	Buy	+2,500	New	+$34.8K	0.01%	408

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paradigm Asset Management's TAK Position: Q1 2026 in Review

Paradigm Asset Management sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 2,500 shares — an estimated $39K sold.

Paradigm Asset Management first reported a position in TAK in Q3 2022 and held it in 14 quarters. The position peaked at $51.1K in Q3 2023. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Paradigm Asset Management reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Paradigm Asset Management sold 2,500 Takeda Pharmaceutical shares in Q1 2026, an estimated $39K.
Paradigm Asset Management first reported a position in Takeda Pharmaceutical in Q3 2022 and held it in 14 quarters.
Paradigm Asset Management's Takeda Pharmaceutical position peaked at $51.1K in Q3 2023.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Paradigm Asset Management's 13F filing for Q1 2026, filed 12 May 2026.